**Ardelyx Inc. (ARDX) stock surged 15% to $7.76 in the last trading session.** This increase occurred on a high trading volume, contributing to a total gain of 15.6% over the past four weeks. The uptick is attributed to growing investor confidence ahead of the company’s fourth-quarter results, driven by strong demand for its drugs, Ibsrela and Xphozah.
In 2025, Ibsrela is projected to generate approximately $274 million in total revenue, a 73% increase from 2024, while Xphozah is expected to bring in around $104 million. Ardelyx is anticipated to report quarterly earnings of $0.02 per share, unchanged from the previous year, with revenues estimated at $118.08 million, marking a 1.7% year-over-year growth. The consensus EPS estimate has also seen an 80% upward revision in the past 30 days, indicating potential for further stock appreciation.
